PDCD1 and head and neck squamous cell carcinoma: However, the response rate to PD-1/PD-1 ligand (PD-L1) inhibitors for recurrent or metastatic HNSCC has been disappointingly low, ranging from 13.3 to 17.9% in clinical trials [14].